|Articles|November 14, 2017

Innovative clinical supply solutions

In today’s challenging environment, every clinical study is different and changes can occur during project development which require unique, responsive solutions. Catalent offers flexible services designed to keep studies moving.

Catalent has over 25 years’ experience in providing comprehensive clinical supply services, and has supported over 5,000 trials globally. Through eight cGMP clinical supply facilities across the U.S., Europe and Asia-Pacific region, and a global network of 50+ depots with a combined capacity of more than 1,400,000 cubic feet of controlled temperature space, Catalent manages more than 150,000 shipments per year to over 80 countries.

 

Catalent’s innovative FastChain™ demand led supply solution enables clinical sites to receive patient kits within a matter of days instead of weeks and can reduce clinical waste from more than 200% to less than 20%.

 

Catalent offers customers a full range of tailored solutions designed to address today’s complex clinical supply challenges, from clinical supply management and forecasting, comparator and reference product sourcing, primary and secondary packaging, labelling, clinical storage from controlled room temperature to cryogenic, global cold chain distribution, and clinical returns and destruction.

 

Speciality handling services are available for temperature, light and oxygen sensitive products, DEA Schedule I-V controlled drug substances and potent/cytotoxic products.

 

Catalent. More products. Better treatments. Reliably supplied™.

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.